Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Sarcoma 1

Conditions

Sarcoma 523Glioblastoma 179Gliosarcoma 178Osteosarcoma 155Dendritic Cell Sarcoma, Interdigitating 114Brain Neoplasms 113Gastrointestinal Stromal Tumors 108Central Nervous System Neoplasms 102Rhabdomyosarcoma 81Lymphoma 79Glioma 79Burkitt Lymphoma 79Lymphoma, Non-Hodgkin 78Recurrence 76Leiomyosarcoma 75Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Lymphoma, Large B-Cell, Diffuse 70Liposarcoma 69Astrocytoma 68Sarcoma, Ewing 67Lymphoma, Follicular 63Neuroblastoma 60Lymphoma, Mantle-Cell 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma, B-Cell, Marginal Zone 56Lymphoma, Large-Cell, Immunoblastic 54Hodgkin Disease 54Leukemia, Myeloid, Acute 53Neuroectodermal Tumors, Primitive, Peripheral 52Neoplasm Metastasis 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Primary Effusion × Sarcoma × Clear all
NCT05907759 2026-06-02

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
28 enrolled
LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡